

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) SEQ ID NO: 214; and
 - (b) the full complement of SEQ ID NO: 214;
 - ~~(c) sequences consisting of at least 20 contiguous residues of SEQ ID NO: 214;~~
 - ~~(d) sequences that hybridize to SEQ ID NO: 214 under highly stringent conditions;~~
 - ~~(e) sequences having at least 75% identity to SEQ ID NO: 214;~~
 - ~~(f) sequences having at least 90% identity to SEQ ID NO: 214 and~~
 - ~~(g) degenerate variants of SEQ ID NO: 214.~~
2. (Cancelled).
3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.
5. (Cancelled).

6. (Cancelled).

7. (Cancelled).

8. (Previously canceled)

9. (Cancelled).

10. (Cancelled).

11. (Previously Presented) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of the polynucleotides of claim 1.

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Currently Amended) A diagnostic kit comprising at least one oligonucleotide according to claim 18.

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).